Creating Clarity for Very High Triglycerides Care

Creating Clarity for Very High Triglycerides (VHTG) Care is a web based education series that covers VHTG from pathophysiology to diagnosis to treatment. The educational series is designed as a 5 segment webinar. 

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals caring for individuals at risk for or living with VHTG.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Review clinical trial evidence on the effects of TG-lowering medications on CVD rates
  • Discuss clinical trial design to address the value of TG-lowering medications on CVD rates

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
Quality Improvement and Healthcare Delivery
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credits™
  • 0.50 CME Certificate of Participation
Course opens: 
12/18/2015
Course expires: 
12/31/2017
Rating: 
0

Sergio Fazio, MD, PhD
William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, Oregon

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity: 
Sergio Fazio, MD: Advisory Board Member and Ad Hoc Consultant, Merck & Co.; Ad Hoc Consultant, Amarin, Kowa, Lupin, Roche Pharmaceuticals, Sanofi

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Connie B. Newman, MD

Available Credit

  • 0.50 AMA PRA Category 1 Credits™
  • 0.50 CME Certificate of Participation